News und Analysen
VALBIOTIS SA: General Meeting of April 17, 2026: All Resolutions Approved
VALBIOTIS SA: General Meeting of April 17, 2026: All Resolutions Approved
VALBIOTIS SA: Valbiotis announces launch of operations in Asia
VALBIOTIS SA: Valbiotis announces launch of operations in Asia
VALBIOTIS SA: Valbiotis raises awareness of cardiometabolic risks with the Cœur en Jeu prevention campaign
VALBIOTIS SA: Valbiotis raises awareness of cardiometabolic risks with the Cœur en Jeu prevention campaign
VALBIOTIS SA: 2025 Commercial roll-out underway, reflected in a strong ramp-up in revenues in Q4
VALBIOTIS SA: 2025 Commercial roll-out underway, reflected in a strong ramp-up in revenues in Q4
VALBIOTIS SA: Valbiotis launches an exclusive commercial benefit for its shareholders: a 20% discount on ValbiotisPRO® and ValbiotisPLUS® ranges
VALBIOTIS SA: Valbiotis launches an exclusive commercial benefit for its shareholders: a 20% discount on ValbiotisPRO® and ValbiotisPLUS® ranges
VALBIOTIS SA: Valbiotis announces a major new scientific publication on TOTUM-448, an active substance designed to treat metabolic liver disease (MASLD)
VALBIOTIS SA: Valbiotis announces a major new scientific publication on TOTUM-448, an active substance designed to treat metabolic liver disease (MASLD)
VALBIOTIS SA: Valbiotis announces an exclusive distribution agreement in the Middle East
VALBIOTIS SA: Valbiotis announces an exclusive distribution agreement in the Middle East
VALBIOTIS SA: Valbiotis recognized by the 2025 Top Santé Award for Valbiotis Plus® Serenity, an innovative solution for emotional balance
VALBIOTIS SA: Valbiotis recognized by the 2025 Top Santé Award for Valbiotis Plus® Serenity, an innovative solution for emotional balance
VALBIOTIS SA: Valbiotis announces completion of recruitment for the Cardio-Liver clinical study conducted with TOTUM•448 for metabolic liver diseases (MASLD)
VALBIOTIS SA: Valbiotis announces completion of recruitment for the Cardio-Liver clinical study conducted with TOTUM•448 for metabolic liver diseases (MASLD)
Correction of a release from 17.11.2025 17:40 CET/CEST - VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
Correction of a release from 17.11.2025 17:40 CET/CEST - VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained preferential subscription rights for a gross amount of nearly €6.9 million, secured by subscription commitments of 75
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained preferential subscription rights for a gross amount of nearly €6.9 million, secured by subscription commitments of 75
VALBIOTIS SA: Valbiotis to launch ValbiotisPRO® Cardio-circulation on 2 June
VALBIOTIS SA: Valbiotis to launch ValbiotisPRO® Cardio-circulation on 2 June
VALBIOTIS SA: Strong Start to the Year in Line with the Company Roadmap: Expanding Sales Network, New Product Launches, & Growth in Pharmacy and Online Sales
VALBIOTIS SA: Strong Start to the Year in Line with the Company Roadmap: Expanding Sales Network, New Product Launches, & Growth in Pharmacy and Online Sales
BILENDI: Bilendi reports record 2025 results and unveils strategic plan to become a global AI-native insights platform
BILENDI: Bilendi reports record 2025 results and unveils strategic plan to become a global AI-native insights platform
BILENDI: BilendiUX expands internationally: Bringing Advanced Self-Service Recruitment to Local UX Teams
BILENDI: BilendiUX expands internationally: Bringing Advanced Self-Service Recruitment to Local UX Teams
ROCTOOL: Compose Manufacturing Expands Roctool-Enabled production capacity in Asia with ten new induction systems
ROCTOOL: Compose Manufacturing Expands Roctool-Enabled production capacity in Asia with ten new induction systems
BILENDI: Bilendi Text Coding Platform: The AI-Native Self-Service Platform Redefining Verbatim Coding
BILENDI: Bilendi Text Coding Platform: The AI-Native Self-Service Platform Redefining Verbatim Coding
ROCTOOL: Roctool to Run Live Molding Demonstrations at JEC World and Introduce Roctool Thermal Fusion - RTF™
ROCTOOL: Roctool to Run Live Molding Demonstrations at JEC World and Introduce Roctool Thermal Fusion - RTF™
BILENDI: Bilendi Discuss: The AI-Native Platform Redefining Global Research
BILENDI: Bilendi Discuss: The AI-Native Platform Redefining Global Research
Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
